Upfront Briefing
FDA did some actual approving: Axsome expanded Auvelity into Alzheimer’s agitation, and Pfizer/Arvinas got vepdegestrant (Veppanu) across the line — despite “underwhelming data.”
On the capital/comp front, UCB agreed to acquire Candid Therapeutics for up to $2.2B, while Esperion lined up a potential $1.1B take-private — because apparently it’s comps o’clock.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,230.1 |
+0.3% |
+5.6% |
| Nasdaq 100 |
27,710.4 |
+0.9% |
+9.9% |
| Russell 2000 |
2,812.8 |
+0.5% |
+13.4% |
| Healthcare (XLV) |
145.2 |
(0.6%) |
(5.6%) |
| Biotech (XBI) |
130.4 |
(0.7%) |
+8.8% |
| Nasdaq Biotech (NBI) |
5,799.3 |
(1.1%) |
+1.2% |
| Clinical Trials (BBC) |
43.8 |
(0.2%) |
+17.1% |
|
- Index level: S&P 500 +0.3% and Nasdaq 100 +0.9% closed at fresh highs as large-cap tech and stronger-than-expected earnings kept the broader risk-on tone alive, helped by lower oil prices and softer Treasury yields.
- Biotech lagged: XBI (0.7%) and NBI (1.1%) underperformed because the marginal headlines were stock-specific and negative — Summit Therapeutics (~23% on the HARMONi-3 interim miss) and AZ camizestrant (ODAC 6-3 against) dragged sentiment despite the broader risk-on bid.
- Healthcare stayed softer (XLV (0.6%)) as the sector failed to participate in the tech-led rally; the Veppanu approval and Auvelity label expansion were not enough to lift sector beta against Summit-led downside dispersion.
- Market data: U.S. close Fri 01-May-2026.
The Big 3
|
1
|
Axsome wins FDA approval for Alzheimer’s agitation
|
- FDA approved Auvelity (dextromethorphan/bupropion) for agitation associated with Alzheimer's dementia — the first non-antipsychotic to clear the bar in the indication and the second neuropsychiatric label for Auvelity (already approved in MDD). Approval was supported by ADVANCE-1 and ACCORD-2; long-term data showed a statistically significant time-to-relapse benefit vs placebo.
- Why it matters: Pure label-expansion event for a commercial CNS asset (Auvelity Q4 run-rate ~$130M+) into a market with ~6M U.S. AD patients and ~50% incidence of agitation — a setting served almost exclusively by Otsuka/Lundbeck's Rexulti (~$2.0B WW), where antipsychotic safety warnings remain a commercial and clinical overhang. Investors have moved past regulatory risk; the debate is now (i) speed of formulary access, (ii) how aggressively Axsome can convert primary-care prescribers without an antipsychotic safety overhang, and (iii) what this approval implies for AXS pipeline visibility on AXS-12 and AXS-14.
- Source: BioSpace
- More: Fierce Pharma; Pharma Tech; STAT
|
|
2
|
FDA approves Pfizer-Arvinas breast cancer drug Veppanu
|
- FDA approved Pfizer/Arvinas's vepdegestrant (Veppanu) for ESR1-mutated ER+/HER2- advanced or metastatic breast cancer post one line of endocrine therapy — ahead of the June 5 PDUFA. Approval based on the ESR1m subgroup (n=270) of the Phase 3 VERITAC-2 trial: median PFS 5.0 months vs 2.1 months for fulvestrant (HR 0.57; p=0.0001) — a 43% reduction in risk of progression or death. Veppanu is the first FDA-approved PROTAC / heterobifunctional protein degrader.
- Why it matters: Platform-defining, but commercially modest near-term. The HR 0.57 in ESR1m is real efficacy, but the absolute PFS delta (~3 months) is a competitive disadvantage vs the developing 2L oral SERD set, and Pfizer/Arvinas have publicly said they're seeking a commercialization partner — meaning launch execution is unowned. For investors: (i) the PROTAC class now has a live label, validating Arvinas's platform and re-rating peer degraders (C4, Kymera, Nurix) with stronger profiles; (ii) the unfilled commercial slot is a near-term overhang on ARVN until a partner is named; (iii) AZ camizestrant's ODAC setback the same week clears competitive runway in the ESR1m switch setting.
- Source: Endpoints
- More: BioPharma Dive; Fierce Pharma; FDA
|
| 3 | UCB buys Candid Therapeutics for up to $2.2B |
- UCB will acquire San Diego-based Candid Therapeutics for up to $2.2B ($2.0B upfront + $200M milestones). Candid's lead asset is cizutamig, a BCMAxCD3 bispecific T-cell engager dosed in 100+ patients (47 with autoimmune disease) and currently in Phase 1 across 10+ autoimmune indications including myasthenia gravis and ILD. Candid was founded in 2024 by Two River and Third Rock Ventures (via TRC 2004 + Vignette Bio merger) and was backed by Venrock Healthcare Capital, Fairmount, TCGX, venBio, Foresite, Vida, OrbiMed, Boxer, Redmile, T. Rowe Price and Viking Global.
- Why it matters: UCB pre-empts Candid's planned public-market route — Candid had already announced a reverse merger into Rallybio (RLYB) in March 2026 with a $505M concurrent crossover. UCB instead pays strategic-control pricing for a private, mostly Phase 1 asset, which (i) sets a new floor for autoimmune T-cell engager comps and gives autoimmune immune-reset peers a fresh valuation anchor; (ii) extends the "oncology-derived B-cell depletion → immune reset" thesis (after AbbVie/Capstan, Lilly/in-vivo CAR-T deals); (iii) removes a high-quality TCE listing from the 2026 IPO pipeline at a moment supply was finally building. The Rallybio break-up obligation (up to $50M payable by Candid) is small relative to deal size.
- Source: PR
- More: WSJ; Endpoints; BPD (Rallybio context)
|
Everything Else that broke
- AZ Truqap (capivasertib) wins FDA ODAC 7-1 backing in PTEN-deficient mHSPC (CAPItello-281; HR 0.81 for rPFS, median 33.2 vs 25.7 mo) — same day as the camizestrant breast cancer rejection. — PR (BioSpace); Fierce
- Summit slips on ivonescimab interim Phase 3 signal. — Endpoints
- Amgen starts MariTide Phase 3 obesity trials, including switch study. — Endpoints
- Moderna in talks with FDA over Phase 4 Covid vaccine data. — Endpoints
- Moderna Q1 revenue tops expectations; litigation overhang. — BioSpace
- J&J axes two CAR-T therapies for lymphoma. — Endpoints
- Samsung Biologics workers begin five-day strike over wages. — Endpoints
- Novartis unveils North Carolina API plant in $23B US expansion. — BioSpace
- Amgen files Tavneos label update as FDA escalates push to withdraw. — Endpoints
- Corcept links ALS drug to improved 2-year survival ahead of Phase 3. — BioSpace
- FDA Action Alert flags upcoming catalysts for Argenx, AstraZeneca/Daiichi, Biogen/Eisai and Cingulate. — BioSpace
- Proposed ban on China clinical trial data raises concerns in Washington. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Esperion to go private in up-to-$1.1B buyout by ArchiMed, with $3.16/share cash upfront plus up to $100M in contingent sales milestones. — PR
-
UCB to acquire Candid Therapeutics for up to $2.2B ($2.0B upfront + $200M milestones), pre-empting Candid's planned reverse merger with Rallybio (RLYB) and a concurrent $505M crossover. Candid was founded by Two River + Third Rock; backers include Venrock, Fairmount, TCGX, venBio, Foresite, Vida, OrbiMed, Boxer, Redmile, T. Rowe Price, Viking Global. — PR
-
Olympus signs global distribution deal with EndoRobotics. — PR
-
Novelty Nobility expands work with AGC Biologics on bispecific. — PR
VC / Private Financings
- No notable new VC / private financings identified since Friday's edition.
IPOs / Follow-Ons
- Hemab (COAG) and Seaport (SPTX) both surged on Friday's Nasdaq debut after upsizing IPOs to a combined $556M; Seaport opened +17% — first solid aftermarket validation for the 2026 IPO cohort beyond Veradermics. — Seeking Alpha; Bloomberg
- Three biotechs raise $850M+ in upsized IPOs, gain in aftermarket. — BioCentury
- Q&A: Seaport execs discuss CNS strategy after IPO trading begins. — Endpoints
|
